Form 4: Rigel Pharmaceuticals Executive Acquires Shares and Options

Dean L. Schorno, EVP & Chief Financial Officer of Rigel Pharmaceuticals, acquired shares and stock options on January 29, 2025, as part of a vesting schedule.

Summary

• Dean L. Schorno, the EVP & Chief Financial Officer of Rigel Pharmaceuticals, acquired 19,717 shares of common stock through the vesting of a Restricted Stock Unit award.
• These shares will vest annually over three years starting February 10, 2026.
• Mr. Schorno also acquired 14,788 stock options with an exercise price of $22.49.
• These options vest monthly over three years from the vesting commencement date of January 29, 2025.
• The reported transactions also include 999 shares acquired under the Issuer's stock purchase plan.
• The share numbers have been adjusted to reflect a one-for-ten reverse stock split effective June 27, 2024.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and insider transactions, which are generally viewed neutrally to positively by the market. The vesting schedule aligns executive interests with company performance.

Positives

• The acquisition of shares and options by a key executive demonstrates confidence in the company's future.
• The vesting schedule of the Restricted Stock Units and options aligns the executive's interests with the long-term performance of the company.

Future Outlook

The vesting of shares and options will occur over the next three years, contingent on the executive's continued service.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when executives acquire or dispose of company securities. It provides transparency into insider transactions.

Comparison to Industry Standards

• The vesting schedules for stock options and restricted stock units are typical for executive compensation packages in the biotechnology industry.
• The one-for-ten reverse stock split is a significant event, but not uncommon for companies seeking to maintain listing requirements or improve share price.

Stakeholder Impact

• Shareholders may view the executive's acquisition of shares and options as a positive sign of confidence in the company's future performance.
• The vesting schedule aligns the executive's interests with the long-term success of the company.

Key Dates

Keywords

Rigel Pharmaceuticals, insider trading, stock options, restricted stock units, share acquisition, executive compensation, Dean L. Schorno, EVP & Chief Financial Officer